SillaJen expands partnership with ABL Europe for oncolytic virus therapies JX-594 & JX-970.
M2 PHARMA-January 23, 2018-SillaJen expands partnership with ABL Europe for oncolytic virus therapies JX-594 & JX-970
(C)2018 M2 COMMUNICATIONS
South Korean biotechnology company SillaJen Inc (KOSDAQ:215600) stated on Monday that it has expanded its strategic manufacturing collaboration in oncolytic virus therapies with ABL Europe, which provides viral vector GMP services for gene therapy , oncolytic products and vaccines for clinical supply.
Pursuant to the current agreement, ABL is currently manufacturing Pexa-Vec (formerly JX-594) for SillaJen's multinational, randomised Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer.
The Pexa-Vec vaccinia strain naturally targets cancer cells due to common genetic defects in cancer cells. Pexa-Vec is engineered to express the immunogenic GM-CSF protein, which complements the cancer cell lysis of the product candidate, leading to tumor necrosis, tumor vasculature shutdown and sustained anti-tumoral immune attack. The ongoing Phase 3 PHOCUS trial is designed to enroll 600 patients who have not received prior systemic treatment for their cancer.
As part of the expanded agreement, ABL will provide development, manufacturing & QC release testing services for SillaJen's pipeline product, JX-970.
According to the company, JX-970 is an oncolytic virus that is derived from a Western Reserve strain vaccinia virus and its tumor selectivity has been optimized through deletion of thymidine kinase (TK) and vaccinia growth factor (VGF). In addition, it expresses GM-CSF to stimulate immune responses.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 23, 2018|
|Previous Article:||Water Street & medical partner awarded US FDA approval for Bivalirudin in first frozen premixed ready-to-use formulation presentation.|
|Next Article:||AnGes seeks PDMA marketing approval for HGF gene therapy for CLI.|